0001145549-21-015455.txt : 20210311 0001145549-21-015455.hdr.sgml : 20210311 20210311093535 ACCESSION NUMBER: 0001145549-21-015455 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210311 DATE AS OF CHANGE: 20210311 EFFECTIVENESS DATE: 20210311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Managed Portfolio Series CENTRAL INDEX KEY: 0001511699 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-22525 FILM NUMBER: 21732087 BUSINESS ADDRESS: STREET 1: 615 EAST MICHIGAN STREET CITY: MILWAUKEE STATE: WI ZIP: 53202 BUSINESS PHONE: 414-287-3700 MAIL ADDRESS: STREET 1: 615 EAST MICHIGAN STREET CITY: MILWAUKEE STATE: WI ZIP: 53202 0001511699 S000046566 Muhlenkamp Fund C000145345 Institutional Class Shares MUHLX 0001511699 S000047869 TorrayResolute Small/Mid Cap Growth Fund C000150334 Investor Class Shares TRSDX C000150335 Institutional Class Shares TRSMX 0001511699 S000057860 Friess Small Cap Growth Fund C000187061 Institutional Class SCGFX C000187062 Investor Class SCGNX N-CEN 1 primary_doc.xml X0303 N-CEN LIVE 0001511699 XXXXXXXX true false false N-1A S000047869 true S000046566 true S000057860 true Managed Portfolio Series 811-22525 0001511699 254900SQ3GG01NP4WM65 615 East Michigan Street Milwaukee 53202 US-WI US 4147656844 U.S. Bancorp Fund Services, LLC 615 E. Michigan St. Milwaukee 53202 18336121912 Transfer agency, fund accounting and fund administration data U.S. Bank National Association 1555 N. Rivercenter Drive Suite 302 Milwaukee 53212 18336121912 Custody data Compass Distributors, LLC Three Canal Plaza Suite 100 Portland 04101 12075537110 Distribution Data Quasar Distributors, LLC 111 East Kilbourn Avenue Suite 2200 Milwaukee 53202 18662516920 Distribution data Foreside Fund Services, LLC Three Canal Plaza Suite 100 Portland 04101 12075537110 Distribution Data Toroso Investments, LLC 898 North Broadway Suite 2 Massapequa 11758 18449867676 Adviser data Coho Partners, Ltd. 300 Berwyn Park 801 Cassatt Road, Suite 100 Berwyn 19312 18662646234 Adviser data Cove Street Capital, LLC 2101 E. El Segundo Boulevard Suite 302 El Segundo 90245 18664970097 Adviser data Friess Associates, LLC P.O. Box 576 Jackson 83001 18556563017 Adviser data Friess Associates of Delaware, LLC P.O. Box 4166 Greenville 19807 18556563017 Adviser data Great Lakes Advisors, LLC 231 S. LaSalle Street 4th Floor Chicago 60604 18552782020 Adviser data Principal Street Partners, LLC 6075 Poplar Avenue Suite 221 Memphis 38119 18779147343 Adviser data Jackson Square Partners, LLC One Letterman Drive Building A, Suite A3-200 San Francisco 94129 18445773863 Adviser data Lawson Kroeker Investment Management, Inc. 450 Regency Parkway Suite 410 Omaha 68114 18556981378 Adviser data Muhlenkamp & Company, Inc. 5000 Stonewood Drive Suite 300 Wexford 15090 18008603863 Adviser data Nuance Investments 4900 Main Street Suite 220 Kansas City 64112 18556826233 Adviser data Olstein Capital Management, L.P. 4 Manhattanville Road Purchase 10577 18007992113 Adviser data Port Street Investments, LLC 24 Corporate Plaza Suite 150 Newport Beach 92660 18553696220 Adviser data Saratoga Research & Investment Management 14471 Big Basin Way Suite E Saratoga 95070 18553696220 Adviser data Reinhart Partners, Inc. 1500 W. Market Street Suite 100 Mequon 53092 18557743863 Adviser data Torray LLC 7501 Wisconsin Avenue Suite 750 W. Bethesda 20814 18444064960 Adviser data Tortoise Index Solutions, LLC. 5100 W. 115th Place Leawood 66211 18888703088 Adviser data Tortoise Capital Advisors, LLC. 5100 W. 115th Place Leawood 66211 18558223863 Adviser data Vident Investment Advisory, LLC 89 Headquarters Plaza North Tower, 14th Floor Morristown 07960 19739153170 Adviser data Ecofin Advisors Limited 15 Buckingham Street Charing Cross London GB WC2N 6DU 4402074512941 Adviser data N N N N-1A 33 Y Robert Kern N/A N Leonard Rush 000726159 N David Massart 002332208 N David Swanson N/A N Deborah Ward N/A 615 E. Michigan Street Milwaukee 53202 XXXXXX N N N N N Quasar Distributors, LLC 8-52323 000103848 N/A N Compass Distributors, LLC 8-69518 000172662 N/A N Foreside Fund Services, LLC 8-51293 000046106 N/A N N Cohen & Company, Ltd. 00925 N/A Ernst & Young LLP 00042 N/A N N N N N N Torray Resolute Small/Mid Cap Growth Fund S000047869 254900J0VHLCLUNPOG95 N 2 0 0 N/A N N Y N N/A N/A N/A Rule 12d1-1 (17 CFR 270.12d1-1) Y Y Y N Torray LLC 801-08629 000105818 N/A N U.S. Bancorp Fund Services, LLC 85-11357 N1GZ7BBF3NP8GI976H15 N N N Intercontinental Exchange Inc. 5493000F4ZO33MV32P92 N N US Bank National Association 6BYL5QZYBDK8S7L73M02 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) The Bank of New York Mellon HPFHU0OQ28E4N0NFVK49 N Y Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N N U.S. Bancorp Fund Services, LLC N1GZ7BBF3NP8GI976H15 N N N William Blair & Company LLC 8-02698 000001252 N/A 2476.000000000000 Jones & Associates Inc 8-26089 000006888 2138008JJ5PA8H5UIL69 1071.000000000000 Strategas Securities, LLC 8-68138 000149326 254900D5NQ2O9DJLKH96 566.000000000000 4113.000000000000 0.000000000000 N 12074468.000000000000 N N N N Muhlenkamp Fund S000046566 549300XTEE75IP3IO553 N 1 0 0 N/A N N Y N N/A N/A N/A Rule 12d1-1 (17 CFR 270.12d1-1) Y Y Y N Muhlenkamp and Company, Inc. 801-16476 000110787 N/A N U.S. Bancorp Fund Services, LLC 85-11357 N1GZ7BBF3NP8GI976H15 N N N Intercontinental Exchange Inc. 5493000F4ZO33MV32P92 N N US Bank National Association 6BYL5QZYBDK8S7L73M02 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) The Bank of New York Mellon HPFHU0OQ28E4N0NFVK49 N Y Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N N U.S. Bancorp Fund Services, LLC N1GZ7BBF3NP8GI976H15 N N N Wall Street Management Inc 8-25936 000010012 549300Z0MOT47D6OQV22 10080.000000000000 Jones and Assosciates Inc 8-26089 000006888 2138008JJ5PA8H5UIL69 8666.000000000000 GAMCO Asset Management, Inc. 801-14132 000104950 549300ROMGG0TPI4F636 4146.000000000000 RBC Capital Markets LLC 8-45411 000031194 549300LCO2FLSSVFFR64 2240.000000000000 Morgan Stanley and Co LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 2000.000000000000 27132.000000000000 Jones and Assosciates Inc 8-26089 000006888 2138008JJ5PA8H5UIL69 40419.000000000000 40419.000000000000 N 162454036.000000000000 Uncommitted 7000000.000000000000 N N N N Friess Small Cap Growth Fund S000057860 549300DL8BJO5EZ6ZH67 N 2 0 0 N/A N N N N U.S. Bank, N.A. 6BYL5QZYBDK8S7L73M02 N N N/A N/A N/A N/A N N N N Friess Associates, LLC 801-16178 000107735 N/A N U.S. Bancorp Fund Services, LLC 85-11357 N1GZ7BBF3NP8GI976H15 N N N Intercontinental Exchange Inc. 5493000F4ZO33MV32P92 N US Bank National Association 6BYL5QZYBDK8S7L73M02 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) The Bank of New York Mellon HPFHU0OQ28E4N0NFVK49 N Y Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N N U.S. Bancorp Fund Services, LLC N1GZ7BBF3NP8GI976H15 N N N Jefferies & Company, Inc. 8-15074 000002347 58PU97L1C0WSRCWADL48 42204.000000000000 Goldman Sachs & Co. 8-00129 000000361 FOR8UP27PHTHYVLBNG30 40160.000000000000 UBS Financial Services, Inc. 8-16267 000008174 ETYRV6ORNFJB5NONI676 37077.000000000000 Morgan Stanley & Co., Inc. 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 30107.000000000000 Jones & Associates, Inc. 8-26089 000006888 2138008JJ5PA8H5UIL69 29288.000000000000 Raymond James & Associates, Inc. 8-10999 000000705 U4ONQX15J3RO8XCKE979 27730.000000000000 RBC Dominion Securities, Inc. 8-45411 000031194 549300LCO2FLSSVFFR64 23139.000000000000 Piper 8-15204 000000665 549300GRQCWQ3XGH0H10 18777.000000000000 MKM Partners 8-53436 000114666 25490041O5W104HFWA62 16344.000000000000 JP Morgan Chase 8-35008 000000079 ZBUT11V806EZRVTWT807 14213.000000000000 476451.000000000000 JP Morgan Chase 8-35008 000000079 ZBUT11V806EZRVTWT807 209215601.000000000000 Merrill Lynch, Inc. 8-33359 000016139 549300PMHS66E71I2D34 194318167.000000000000 Citigroup Global Markets, Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 82633737.000000000000 Williams Capital Group LP 8-46623 000035149 254900QGK3PNRGR9BD85 21998520.000000000000 Goldman Sachs & Co. 8-00129 000000361 FOR8UP27PHTHYVLBNG30 1602536.000000000000 Oppenheimer & Co. 8-04077 000000249 254900VH02JQR2L8XD64 1568301.000000000000 B Riley & Co. LLC 8-49016 000040355 549300AEVMODVBY3QS51 536265.000000000000 Morgan Stanley & Co., Inc. 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 65722.000000000000 Jeffries & Company, Inc. 8-15074 000002347 58PU97L1C0WSRCWADL48 57300.000000000000 Dougherty & Company LLC 8-21937 000007477 549300OD1C69R64IVC38 17000.000000000000 512013148.000000000000 N true INTERNAL CONTROL RPT 2 torrayresandmk.htm TORRAYRESOLUTE AND MUHLENKAMP AUDIT INTERNAL CONTROL LETTER

  

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

  

To the Shareholders and Board of Trustees of  

Managed Portfolio Series 

  

In planning and performing our audit of the financial statements of Muhlenkamp Fund and TorrayResolute Small/Mid Cap Growth Fund (the “Funds”) as of and for the year ended December 31, 2020, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Funds’ internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting.  Accordingly, we express no such opinion. 

  

The management of the Funds is responsible for establishing and maintaining effective internal control over financial reporting.  In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls.  A fund’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (GAAP).  A fund’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the fund; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the fund are being made only in accordance with authorizations of management and trustees of the fund; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a fund’s assets that could have a material effect on the financial statements.  

  

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. 

  

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis.  A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Funds’ annual or interim financial statements will not be prevented or detected on a timely basis. 

  

Our consideration of the Funds’ internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the PCAOB.  However, we noted no deficiencies in the Funds’ internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of December 31, 2020.  

  

This report is intended solely for the information and use of management and the Board of Trustees of the Funds and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties. 

  

/s/ COHEN & COMPANY, LTD. 

  

COHEN & COMPANY, LTD. 

Cleveland, Ohio  

February 25, 2021 

  

  

INTERNAL CONTROL RPT 3 friess.htm FRIESS AUDIT INTERNAL CONTROL LETTER

  

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

  

To the Shareholders of Friess Small Cap Growth Fund and 

Board of Trustees of Managed Portfolio Series 

  

In planning and performing our audit of the financial statements of Friess Small Cap Growth Fund (the “Fund”), a series of Managed Portfolio Series, as of and for the year ended December 31, 2020, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund’s internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund’s internal control over financial reporting.  Accordingly, we express no such opinion. 

  

The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting.  In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls.  A fund’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (GAAP).  A fund’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the fund; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the fund are being made only in accordance with authorizations of management and trustees of the fund; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a fund’s assets that could have a material effect on the financial statements.  

  

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. 

  

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis.  A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Fund’s annual or interim financial statements will not be prevented or detected on a timely basis. 

  

Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of December 31, 2020.  

  

This report is intended solely for the information and use of management and the Board of Trustees of the Fund and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties. 

  

/s/ COHEN & COMPANY, LTD. 

  

COHEN & COMPANY, LTD. 

Cleveland, Ohio  

January 22, 2021